



HIST1H1E heterozygous protein-truncating variants cause a recognizable syndrome with intellectual disability and distinctive facial gestalt

DOI:

[10.1002/ajmg.a.61321](https://doi.org/10.1002/ajmg.a.61321)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Burkardt, D. DC., Zachariou, A., Loveday, C., Allen, C. L., Amor, D. J., Ardisson, A., Banka, S., Bourgois, A., Coubes, C., Cytrynbaum, C., Faivre, L., Marion, G., Horton, R., Kotzot, D., Lay-Son, G., Lees, M., Low, K., Luk, H.-M., Mark, P., ... Tatton-Brown, K. (2019). HIST1H1E heterozygous protein-truncating variants cause a recognizable syndrome with intellectual disability and distinctive facial gestalt: A study to clarify the HIST1H1E syndrome phenotype in 30 individuals. *American Journal of Medical Genetics. Part A*, 179(10), 2049-2055. <https://doi.org/10.1002/ajmg.a.61321>

Published in:

American Journal of Medical Genetics. Part A

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



1 ***HIST1H1E* Heterozygous Protein Truncating Variants Cause a Recognizable Syndrome**
2 **with Intellectual Disability and Distinctive Facial Gestalt: A Study to Clarify the**
3 ***HIST1H1E* Syndrome Phenotype in 30 individuals.**

4 Deepika D'Cunha Burkardt¹, Anna Zachariou², Chey Loveday², Clare L Allen³, David J. Amor⁴,
5 Anna Ardisson⁵, Siddharth Banka^{6,7}, Alexia Bourgois⁸, Christine Coubes⁹, Cheryl
6 Cytrynbaum¹⁰, Laurence Faivre¹¹, Gerard Marion¹², Rachel Horton¹³, Dieter Kotzot¹⁴, Guillermo
7 Lay-Son¹⁵, Melissa Lees¹⁶, Karen Low¹⁷, Ho-Ming Luk¹⁸, Paul Mark¹⁹, Allyn McConkie-
8 Rosell²⁰, Marie McDonald MD²⁰, John Pappas²¹, Christophe Phillippe²², Deborah Shears²³, Brian
9 Skotko²⁴, Fiona Stewart²⁵, Helen Stewart²⁶, I Karen Temple²⁷, Frederic Tran Mau-Them²⁸,
10 Ricardo A. Verdugo²⁹, Rosanna Weksberg¹⁰, Yuri A. Zarate³⁰, John M Graham³¹, Katrina
11 Tatton-Brown^{2,32,33*}

12
13 1: University Hospitals Rainbow Babies and Children, Cleveland, OH /Case Western Reserve
14 University, Cleveland, OH, USA

15 2: Institute of Cancer Research, London, UK

16 3: Lowerbank Dental Practice, Leyland, UK

17 4: Murdoch Children's Research Institute and University of Melbourne Department of
18 Paediatrics, The Royal Children's Hospital, Parkville, Victoria, Australia

19 5: Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia, Italy

20 6: Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of
21 Biology, Medicine and Health, University of Manchester, Manchester, UK.

22 7: Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS
23 Foundation Trust, Health Innovation Manchester, Manchester, U.K.

- 24 8: CHU Côte de Nacre, Service de Génétique, Caen, Fr
- 25 9: Hôpital Arnaud de Villeneuve Montpellier, Fr
- 26 10: The Hospital for Sick Children, Div of Clinical and Metabolic Genetics, Toronto, ON, CA
- 27 11: Genetics center, Genetics, Hôpital d'Enfants, Dijon, FR
- 28 12: Centre Hospitalier Universitaire de Caen Normandie, Service de génétique
- 29 Caen, FR
- 30 13: University Hospital Southampton NHS Foundation Trust Southampton, Southampton, UK
- 31 14: Division of Clinical Genetics, Department of Pediatrics, Paracelsus Medical University
- 32 Salzburg, Salzburg, Austria.
- 33 15: Pontificia Universidad Católica de Chile, División de Pediatría, Santiago, CL
- 34 16: Great Ormond Street Hospital For Children NHS Foundation Trust, Clinical Genetics
- 35 department, London, UK
- 36 17: University Hospitals Bristol, Clinical Genetics, St Michaels Hospital, Southwell Street
- 37 Bristol, Bristol, UK
- 38 18: Department of Health, Clinical Genetic Service, Hong Kong, HK
- 39 19: Spectrum Health Division of Medical Genetics, Grand Rapids, MI, USA
- 40 20: Duke University Medical Genetics, Department of Pediatrics, Division of Medical Genetics,
- 41 Durham, NC, USA
- 42 21: New York University School of Medicine, Human Genetics Program New York, NY, USA
- 43 22: UF Innovation en diagnostic génomique des maladies rares, CHU Dijon Bourgogne, and
- 44 INSERM UMR1231 GAD, F-21000, Dijon, France
- 45 23: Churchill Hospital, Clinical Genetics, Oxford, UK

46 24: Division of Medical Genetics and Genomics, Department of Pediatrics, Massachusetts
47 General Hospital, Boston, USA and Department of Pediatrics, Harvard Medical School, Boston,
48 USA

49 25: Belfast City Hospital, Medical Genetics, Belfast, UK

50 26: Oxford University Hospitals NHS Foundation Trust, clinical genetics, Oxford Centre for
51 Genomic Medicine ACE building Nuffield Orthopaedic Centre Oxford University Hospitals
52 NHS Foundation Trust Windmill Road Headington, Oxford, UK

53 27: Faculty of Medicine, University of Southampton and Wessex Clinical Genetics Service,
54 University Hospital Southampton, Southampton, UK

55 28: Centre Hospitalier Universitaire de Dijon, FHU TRANSLAD, Dijon, Bourgogne, FR /
56 Centre Hospitalier Universitaire de Dijon, UF d'innovation en génétique moléculaire, Plateau
57 technique de biologie, CHU, Dijon, FR

58 29: ICBM, Programa de Genética Humana, Santiago, CL

59 30: Arkansas Children's Hospital, Section of Genetics and Metabolism, Little Rock, AR, USA

60 31: Medical Genetics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

61 32. South West Thames Regional Genetics Service, St George's University Hospitals NHS
62 Foundation Trust, London, UK

63 33: St George's University of London, London, UK.

64 * denotes Corresponding Author

65 **Abstract**

66 *Histone Gene Cluster 1, Member E, HIST1H1E*, encodes histone H1.4 and is one of a family of
67 epigenetic regulator genes that acts as a linker histone protein and is responsible for higher order
68 chromatin structure. HIST1H1E syndrome (also known as Rahman syndrome, OMIM #617537)
69 is a recently described intellectual disability syndrome. Since the initial description of five
70 unrelated individuals with three different heterozygous protein truncating variants (PTVs) in the
71 *HIST1H1E* gene in 2017, we have recruited 30 patients, all with *HIST1H1E* PTVs that result in
72 the same shift in frame and that cluster to a 94 base pair region in the *HIST1H1E* carboxy
73 terminal domain (CTD). The identification of 30 patients with *HIST1H1E* variants has allowed
74 the clarification of the HIST1H1E syndrome phenotype. Major findings include an intellectual
75 disability and a recognizable facial appearance. Intellectual disability was reported in all patients
76 and is most frequently of moderate severity. The facial gestalt consists of a high frontal hairline
77 and full lower cheeks in early childhood and, in later childhood and adulthood, affected
78 individuals have a strikingly high frontal hairline, frontal bossing and deep-set eyes. Other
79 associated clinical features include hypothyroidism, abnormal dentition, behavioral issues,
80 cryptorchidism and cardiac anomalies. Brain MRI imaging is frequently abnormal with a slender
81 corpus callosum a frequent finding.

82 **Keywords:** *HIST1H1E*, intellectual disability, Epigenetic regulator gene, Rahman Syndrome

83

84 **Introduction**

85 HIST1H1E syndrome (also known as Rahman syndrome, OMIM #617537) is a recently
86 described intellectual disability syndrome caused by protein truncating variants (PTVs) in the
87 *Histone Gene Cluster 1, Member E, HIST1H1E* (Tatton-Brown et al., 2017). *HIST1H1E*, is
88 located at chromosome 6p22.2 and encodes the ubiquitously expressed human linker Histone
89 H1.4, one of a family of linker histones that has historically been thought to determine higher
90 order chromatin structure facilitating DNA replication, DNA repair and genome stability
91 (Fyodorov et al., 2018). More specifically, Histone H1.4 is preferentially sequestered to
92 heterochromatin regions: in the presence of Histone H1.4, nucleosome arrays arrange into a
93 twisted left-hand double helix with a zig-zag two-start tetranucleosome (Roque et al., 2016, Song
94 et al., 2014, Ponte et al., 2017, McGinty et al., 2015).

95 Since the HIST1H1E syndrome was first described as an intellectual disability syndrome (in
96 association with increased growth) in 2017, a total of seven patients have been reported (Tatton-
97 Brown et al. 2017; Takenouchi et al., 2018; Duffney et al., 2018). Here we describe 30 patients
98 with HIST1H1E syndrome with 14 different pathogenic variants, all PTVs causing the same shift
99 in frame and clustering to a 94 base pair region in the *HIST1H1E* carboxy terminal domain.
100 Through a detailed clinical evaluation of these 30 patients, we describe a recurrent and
101 recognizable HIST1H1E syndrome phenotype characterized by a distinctive facial appearance
102 and moderate intellectual disability in association with a range of medical problems.

103

104 **Subjects and Methods**

105 The study was approved by the UK Research Ethics Committee (10/H0305/83), granted by the
106 Cambridge South Research Ethics Committee and the London Multicentre Research Ethics
107 Committee (MREC MREC/01/2/44). Thirty patients with *HIST1H1E* variants, identified through
108 exome sequencing in the diagnostic and research environments, were recruited through clinical
109 genetics services worldwide and family support groups (<https://www.facebook.com/hist1h1e/>)
110 (including five previously reported patients, Tatton-Brown et al., 2017, and one patient included
111 in a paper submitted for publication, details in supplementary table 1). The *HIST1H1E* variants
112 were reported with reference to the canonical transcript (NM_005321.2). Informed consent was
113 obtained from all participants and/or parents. Photographs, with accompanying written informed
114 consent to publish, were requested from all participants and received from 21.

115 Detailed phenotype data were collected through clinic evaluation by at least one of the authors
116 (all experienced dysmorphologists) and standardized clinical proformas. Growth parameter
117 standard deviations were calculated with reference to UK90 growth data (Cole et al., 2012).
118 Intellectual disability was classified by the recruiting clinician as mild, moderate, or severe and
119 unclassified where a child was demonstrating developmental delay but was judged by the
120 clinician as being too young to determine the severity of the intellectual disability. For the
121 purposes of our study the following working definitions were used: mild intellectual disability
122 typically described where an individual had delayed milestones but would attend a mainstream
123 school with some support and live independently, with support, as an adult; moderate intellectual
124 disability typically described where an individual required high-level support in a mainstream
125 school or special educational needs schooling and would live with support as an adult; severe

126 intellectual disability typically described where an individual required special educational needs
127 schooling, had limited speech, and would not live independently as an adult.

128 Protein net charge calculations were undertaken for the wild type and mutant carboxy terminal
129 domain (from p.Lys110 onward) at neutral pH using the Peptide Property Calculator at the
130 Innovagen website and methods as previously described (Tatton-Brown et al., 2017).

131 **Results**

132 *Spectrum of HIST1H1E variants*

133 Thirty unrelated individuals with 14 frameshift *HIST1H1E* variants were identified (Figure 1,
134 Supplementary Table 1). Recurrent variants occurred at c.430dupG_p.(Ala144Glyfs*52) (12
135 patients); c.441dupC_p.(Lys148Glnfs*48) (four patients); c.435dupC_p.(Thr146Hisfs*50) (two
136 patients) and c.436_458del23_p.(Thr146Aspfs*42) (two patients).

137 All variants were absent from the gnomAD database, clustered to a 94 base pair region in the
138 carboxy terminal domain (CTD) and were predicted to result in the same shift in the reading
139 frame (Figure 1, Supplementary Figure 1). The predicted mutant proteins shared the same 38
140 amino acid carboxy terminal motif and all were predicted to have a reduced net positive charge
141 at pH 7 of -6 to 10.9 compared to the predicted wild type protein charge of 41 (Supplementary
142 Figure 1).

143 *HIST1H1E phenotype*

144 Phenotype data for the 30 patients, including 13 males and 17 females with ages ranging from
145 nine months to 30 years, are detailed in Supplementary Table 1. Notable themes included a

146 recognizable facial gestalt with abnormal dentition, a consistent intellectual disability often with
147 behavioral problems and associated medical problems including hypotonia, cryptorchidism in
148 boys, congenital cardiac anomalies, hypothyroidism, a range of skeletal anomalies and brain
149 MRI abnormalities (Figure 2).

150 *Facial Gestalt*

151 There were shared facial features amongst children and adults with HIST1H1E syndrome (Figure
152 3). In early childhood, patients had full cheeks and at all ages patients frequently had a high
153 hairline, bi-temporal narrowing, deep set eyes, downslanting palpebral fissures and
154 hypertelorism and often appeared older than their chronological age (Figure 3A and 3B).

155 *Learning and Behavior*

156 All 30 patients were described as having an intellectual disability but only 24 patients were old
157 enough to determine their degree of cognitive impairment: 17% (4/24) patients were reported
158 with a severe intellectual disability, 79% (19/24) patients were reported with a moderate
159 intellectual disability and 4% (1/24) patients were reported with a mild intellectual disability. Of
160 note, many families report a particular deficit in expressive language acquisition, discrepant with
161 other cognitive skills such as understanding. In addition, behavioral issues were common (50%;
162 15/30) and included combinations of anxiety; attention deficit hyperactivity disorder; autistic
163 spectrum disorder/traits; head banging and aggression (Figure 2, Supplementary Table 1).

164 *Associated Clinical Features*

165 Hypotonia was a common feature 63% (19/30), frequently presenting in the neonatal period.
166 Brain MRI imaging had been undertaken in 15 patients and was reported abnormal in 13 (86%)
167 with corpus callosum abnormalities the most frequent finding (Figure 2).
168 Cryptorchidism was reported in in 69% (9/13) of boys. Abnormal dentition including dental
169 erosions, thin enamel, crumbling teeth and multiple dental caries was reported in 43% (13/30)
170 patients (Figure 3C).
171 Cardiac abnormalities were reported in 43% (13/30) patients, and included combinations of atrial
172 septal defect (nine patients), ventricular septal defect (three patients), patent foramen ovale (one
173 patient), patent ductus arteriosus (one patient) and persistent superior vena cava (one patient).
174 Skeletal anomalies were reported in 40% (12/30) and included combinations of kypho/scoliosis
175 (four patients), camptodactyly (three patients), lower limb asymmetry (two patients) and
176 craniosynostosis, distal brachydactyly, multiple fractures and overlapping toes (one patient
177 each). Hypothyroidism had been diagnosed in five patients (29%, where 17 patients had been
178 tested). Ectodermal abnormalities were reported in six patients including thin and/or brittle, slow
179 growing hair, lack of body hair and thin nails.

180 *Growth*

181 The mean birth weight was 0.2 standard deviations above the mean (0.2SD), mean birth length
182 was 0.3SD and the mean birth head circumference was 1.4SD. Postnatally, the mean height was
183 0.4SD (range of -1.8SD to 8.3SD); the mean weight was 1.1 SD (range of -1.8SD to 4.6SD) and
184 the mean head circumference was 1.1SD (range of -1.7 to 3.7SD) (Figure 4).

185 **Discussion**

186 The aim of this study was to define the HIST1H1E syndrome phenotype in order to propose
187 evidence-based management guidance. Through the detailed clinical evaluation of 30 patients
188 with likely/pathogenic *HIST1H1E* variants, we have shown that an intellectual disability (most
189 frequently moderate) and a characteristic facial gestalt are consistent HIST1H1E associations.
190 Other frequent clinical findings include behavioral issues (especially anxiety); cryptorchidism;
191 hypotonia; abnormal dentition; congenital cardiac anomalies; hypothyroidism; ectodermal
192 findings and brain MRI findings (most frequently corpus callosum abnormalities). Contrary to
193 the initial report, height and/or head circumference were not consistently increased >2SD. We
194 propose the name **HIST1H1E** syndrome as an acronym to help remember the characteristic
195 features of this emerging, recognizable phenotype: **H** for Hypotonia, **I** for Intellectual Disability
196 (ID) with behavioral Issues, **S** for Skeletal, **T** for Testes (undescended) and Thyroid, **H** for Heart
197 anomalies and **E** for Ectodermal issues (including sparse hair and abnormal dentition).

198 Based upon the current phenotypic evaluation, we suggest children with *HIST1H1E* variants are
199 regularly reviewed by a pediatrician to assess development and determine appropriate referral to
200 speech and language therapy and physical therapy; that children have a regular (at least six
201 monthly) dental review to mitigate potentially preventable issues arising from abnormal dentition
202 and that annual thyroid function tests are undertaken. Given the association with congenital
203 cardiac anomalies, we propose a baseline echocardiogram investigation is undertaken with
204 cardiology follow up dependent upon findings. Although *HIST1H1E* somatic variants have been
205 associated with chronic lymphocytic leukemia as well as diffuse large B-cell lymphoma and
206 hepatocellular carcinoma, these are more usually nonsynonymous variants distributed throughout
207 the gene (Chang et al., 2019). None of the patients in this current clinical series developed

208 cancer. We do not therefore currently advocate specific tumor surveillance but any possible
209 tumor related symptoms should be investigated.

210 The 14 *HIST1H1E* variants identified in the 30 patients, all cluster to 94 base pair region in the
211 CTD tail of HIST1H1E. This replicates our initial finding that HIST1H1E syndrome variants are
212 frameshift variants that generate a mutant protein with the same 38 amino acid tail, the result of
213 the same shift in the reading frame (Tatton-Brown et al., 2017). To date, no patient with the
214 HIST1H1E syndrome phenotype has been described with a *HIST1H1E* whole gene deletion, stop
215 gain variant or frameshift variant that results in an alternate shift in reading frame (the latter is
216 not predicted to be associated with a net reduction in charge, Tatton-Brown et al., 2017). In
217 addition, none *HIST1H1E* frameshift variants reported in gnomAD cluster to the same 94 base
218 pair region, nor do they result in the same shift in frame and the generation of a mutant protein
219 with the common 38 amino acid tail. This suggests that the HIST1H1E syndrome phenotype is
220 attributable to a specific set of variants with a defined effect on the protein. Our current working
221 hypothesis is that, because *HIST1H1E* is a single exon, intronless gene, the *HIST1H1E* variants
222 escape nonsense-mediated RNA decay and the resultant mutant HIST1H1E proteins are
223 characterized by a reduced net positive charge compared to wild type proteins, potentially
224 disrupting the normal binding between positively charged HIST1H1E and negatively charged
225 DNA (Tatton-Brown et al., 2017). Further work is required to investigate this.

226 An important remaining question that our current study has not been able to answer is whether
227 the underlying *HIST1H1E* genetic variant determines the range and severity of clinical features.
228 Currently too few patients have been identified to perform robust genotype-phenotype analyses.
229 However, as greater numbers of patients with the HIST1H1E syndrome are identified it will be
230 interesting to further clarify the HIST1H1E phenotype, better delineate the spectrum of causative

231 *HIST1H1E* variants and investigate the relationship between genetic variant and clinical
232 presentation.

233 **Acknowledgements:**

234 We thank the patients and families for their active participation in this study and the clinicians
235 that recruited them. We acknowledge support from the NIHR RM/ICR Biomedical Research
236 Centre. KT-B is supported by funding from the Child Growth Foundation (GR01/13) and the
237 work was, in part, supported by a Wellcome Trust Award (100210/Z/12/Z). This study makes
238 use of DECIPHER (<http://decipher.sanger.ac.uk>), which is funded by Wellcome. The DDD study
239 presents independent research commissioned by the Health Innovation Challenge Fund (grant
240 number HICF-1009-003). See Nature PMID:25533962 or www.ddduk.org/access.html for full
241 acknowledgement.

242 **Conflicts of Interest**

243 The authors declare that they have no conflict of interest.

244 **URLs**

245 Uniprot: <https://www.uniprot.org/>

246 Facebook Parent Support Group: <https://www.facebook.com/hist1h1e/>

247 Genome Aggregation Database (gnomAD), <https://gnomad.broadinstitute.org/>

248 HIST1H1E reference transcript, https://www.ncbi.nlm.nih.gov/nuccore/NM_005321

249 OMIM, <https://www.omim.org/>

250 Protein calculator, <http://pepcalc.com/protein-calculator.php>

251 SMART: <https://smart.embl.de>

252 Protein Atlas (HIST1H1E): <https://www.proteinatlas.org/ENSG00000168298-HIST1H1E/tissue>

253 **References**

254 Tatton-Brown K, Loveday C, Yost S, Clarke M, Ramsay E, Zachariou A, Elliott A, Wylie H,

255 Ardisson A, Rittinger O, Stewart F, Temple IK, Cole T; Childhood Overgrowth

256 Collaboration, Mahamdallie S, Seal S, Ruark E, Rahman N. Mutations in Epigenetic

257 Regulation Genes Are a Major Cause of Overgrowth with Intellectual Disability. *Am J*

258 *Hum Genet.* 2017 May 4;100(5):725-736. doi: 10.1016/j.ajhg.2017.03.010. PubMed

259 PMID: 28475857; PubMed Central PMCID: PMC5420355.

260 Fyodorov DV, Zhou BR, Skoultchi AI, Bai Y. Emerging roles of linker histones in regulating

261 chromatin structure and function. *Nat Rev Mol Cell Biol.* 2018Mar;19(3):192-206. doi:

262 10.1038/nrm.2017.94. Epub 2017 Oct 11. Review. PubMed PMID: 29018282; PubMed

263 Central PMCID: PMC5897046.

264 Roque A, Ponte I, Suau P. Post-translational modifications of the intrinsically disordered

265 terminal domains of histone H1: effects on secondary structure and chromatin

266 dynamics. *Chromosoma.* 2017 Feb;126(1):83-91. doi: 10.1007/s00412-016-0591-8.

267 Epub 2016 Apr 21. Review. PubMed PMID: 27098855.

268 Song F, Chen P, Sun D, Wang M, Dong L, Liang D, Xu RM, Zhu P, Li G. Cryo-EM study of the

269 chromatin fiber reveals a double helix twisted by tetranucleosomal units. *Science.* 2014

270 Apr 25;344(6182):376-80. doi: 10.1126/science.1251413. PubMed PMID: 24763583.

271 Ponte I, Romero D, Yero D, Suau P, Roque A. Complex Evolutionary History of the Mammalian

272 Histone H1.1-H1.5 Gene Family. *Mol Biol Evol.* 2017 Mar 1;34(3):545-558. doi:

273 10.1093/molbev/msw241. PubMed PMID: 28100789; PubMed Central PMCID:
274 PMC5400378.

275 McGinty RK, Tan S. Nucleosome structure and function. *Chem Rev.* 2015 Mar 25;115(6):2255-
276 73. doi: 10.1021/cr500373h. Epub 2014 Dec 12. Review. PubMed PMID: 25495456;
277 PubMed Central PMCID: PMC4378457.

278 Walport LJ, Hopkinson RJ, Chowdhury R, Zhang Y, Bonnici J, Schiller R, Kawamura A,
279 Schofield CJ. Mechanistic and structural studies of KDM-catalysed demethylation of
280 histone 1 isotype 4 at lysine 26. *FEBS Lett.* 2018 Oct;592(19):3264-3273. doi:
281 10.1002/1873-3468.13231. Epub 2018 Sep 14. PubMed PMID: 30156264; PubMed
282 Central PMCID: PMC6220849.

283 Takenouchi T, Uehara T, Kosaki K, Mizuno S. Growth pattern of Rahman syndrome. *Am J Med*
284 *Genet A.* 2018 Mar;176(3):712-714. doi: 10.1002/ajmg.a.38616. Epub 2018 Jan 31.
285 PubMed PMID: 29383847.

286 Duffney LJ, Valdez P, Tremblay MW, Cao X, Montgomery S, McConkie-Rosell A, Jiang YH.
287 Epigenetics and autism spectrum disorder: A report of an autism case with mutation in
288 H1 linker histone HIST1H1E and literature review. *Am J Med Genet B Neuropsychiatr*
289 *Genet.* 2018 Jun;177(4):426-433. doi: 10.1002/ajmg.b.32631. Epub 2018 Apr 27.
290 Review. Erratum in: *Am J Med Genet B Neuropsychiatr Genet.* 2019 Jun;180(4):287.

291 Cole TJ, Wright CM, Williams AF; RCPCH Growth Chart Expert Group. Designing the new
292 UK-WHO growth charts to enhance assessment of growth around birth. *Arch Dis Child*

293 Fetal Neonatal Ed. 2012 May;97(3):F219-22. doi: 10.1136/adc.2010.205864. Epub
294 2011 Mar 11.

295 Chang, S., Yim, S., & Park, H. (2019). The cancer driver genes IDH1/2, JARID1C/ KDM5C, and
296 UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming
297 in cancer metabolism. *Experimental & molecular medicine*, 51(6), 66.
298 doi:10.1038/s12276-019-0230-6

299

300 **Figure Legends**

301 **Figure 1.** Protein schematic showing the 94 base pair clustering of the 14 different protein
302 truncating variants (each variant is designated by a red circle)

303 **Figure 2.** The key clinical features that characterize the HIST1H1E syndrome.

304 **Figure 3. A)** The facial gestalt consists of a high frontal hairline and full lower cheeks in early
305 childhood and, in later childhood and adulthood, affected individuals have a strikingly
306 high frontal hairline, bi-temporal narrowing, frontal bossing and deep-set eyes.

307 **B)** The evolving facial gestalt in three individuals at ages stated.

308 **C)** The dental phenotype includes erosions, thin enamel, crumbling teeth and multiple
309 dental caries. Dental X-rays of an adolescent patient demonstrate thin enamel and short
310 dental roots.

311 **Figure 4.** Growth parameters (with height on x axis and head circumference on y axis) plotted
312 by standard deviation, calculated with reference to UK90 growth data. Although in
313 individual patients, the height and/or head circumference might be increased above two
314 standard deviations, in most patients the growth parameters cluster around the mean.

315 **Supplementary Figure 1:** Wild type and mutant HIST1H1E (generated by the 14 different
316 *HIST1H1E* frameshift variants) showing the reduction in net charge of the carboxy
317 terminal domain motif (from Lys110) at neutral pH7. Mutant proteins share a common
318 38 amino acid tail.

319

